Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1002/acm2.14322

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1177/15330338241232557

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1002/mp.16887

Authorship：Lead author   Language：Japanese   Publishing type：(MISC) Introduction and explanation (scientific journal)  

Language：Japanese   Publishing type：(MISC) Introduction and explanation (scientific journal)  

Language：Japanese   Publishing type：Research paper (scientific journal)  

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1093/jrr/rrad085

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1002/acm2.14212

Language：Japanese   Publishing type：Research paper (scientific journal)  

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1111/1759-7714.15137

Authorship：Last author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.3390/cancers15174382

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1007/s00261-023-03995-x

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

To report the long-term quality assurance (QA) experience of an on-rail computed tomography (CT) system for image-guided radiotherapy using an in-house phantom. An on-rail CT system combining the Elekta Synergy and Canon Aquilion LB was used. The treatment couch was shared by the linear accelerators and CT, and the couch was rotated by 180° when using the on-rail-CT system to ensure that the CT direction was toward the head. All QA analyses were performed by radiation technologists on CBCT or on-rail CT images of the in-house phantom. The CBCT center accuracy from the linac laser, couch rotational accuracy (CBCT center vs. on-rail CT center), horizontal accuracy by CT gantry shift, and remote couch shift accuracy were evaluated. This study reported the QA status of the system during the period 2014-2021. The absolute mean accuracy of couch rotation was 0.4 ± 0.28 mm, 0.44 ± 0.36 mm, and 0.37 ± 0.27 mm in the SI, RL, and AP directions, respectively. Horizontal and remote movement accuracies of the treatment couch were also within 0.5 mm of the absolute mean value. A decrease in the accuracy of couch rotation was also observed due to aging deterioration of related parts caused by the frequent use of couch rotation. The three-dimensional accuracy of on-rail CT systems derived mainly from treatment couches can be maintained within 0.5 mm with appropriate accuracy assurance for at least > 8 years.

DOI： 10.1007/s12194-023-00718-1

PubMed

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1002/acm2.13971

Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author   Language：Japanese   Publishing type：(MISC) Introduction and explanation (commerce magazine)  

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

Authorship：Lead author,　Corresponding author   Language：Japanese   Publishing type：(MISC) Prompt report, short report, and research note, etc. (scientific journal)   Publisher：(株)メディカルアアイ  

Authorship：Last author   Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Greatpoland Cancer Center and Polish Society of Radiation Oncology  

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

DOI： 10.1016/j.adro.2020.07.012

PubMed

Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/j.meddos.2020.09.001

PubMed

Language：English   Publishing type：Research paper (scientific journal)  

The purpose of the study was to investigate the association between tumor volume changes during stereotactic body radiation therapy (SBRT) and prognoses in stage I non-small-cell lung cancer (NSCLC). This retrospective review included stage I NSCLC patients in whom SBRT was performed at a total dose of 48.0-50.5 Gy in four or five fractions. The tumor volumes observed on computed tomography (CT) simulation and on the CT performed at the last treatment session using a CT-on-rails system were measured and compared. Then, the tumor volume changes during the SBRT period were measured and assessed for their association with prognoses (overall survival, local control, lymph node metastases and distant metastases). A total of 98 patients with a mean age of 78.6 years were enrolled in the study. The T-stage was T1a in 42%, T1b in 32% and T2a in 26% of the cases. The gross tumor volume (GTV) shrank and increased ≥10% in 23 (23.5%) and 36 (36.7%) of the cases, respectively. The 5-year local control and overall survival rates in the groups with a tumor shrinkage of ≥10% vs the group with a shrinkage of <10% were 94.7 vs 70.8% and 85.4 vs 47.6%, respectively; these differences were significant, with a P-value < 0.05. During a short SBRT period, the tumor shrank or enlarged in a small number of cases. A decrease of ≥10% in the GTV during SBRT was significantly related to better overall survival and local control.

DOI： 10.1093/jrr/rraa040

PubMed

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Wiley  

DOI： 10.1002/acm2.13005

PubMed

Other Link： https://onlinelibrary.wiley.com/doi/full-xml/10.1002/acm2.13005

Language：English   Publishing type：Research paper (scientific journal)  

We retrospectively reviewed the effect of stereotactic body radiation therapy (SBRT) in patients with stage I lung cancer whose lung tumor showed a nodular appearance of ground glass opacity, so-called ground glass nodule (GGN). A total of 84 patients (42 men, 42 women; mean age, 75 years) with stage I lung cancer with GGN accompanying a solid component <50% in diameter of the tumor and no metastases were studied. Concerning histology, 32 tumors were adenocarcinoma, 1 was squamous cell carcinoma, 2 were unclassified carcinoma and 49 cases were histology-unproven but increased in size or had a positive finding in 18F-FDG positron emission tomography (PET) examination. The median tumor size was 20 mm (range, 10-41 mm). All of the patients were treated with SBRT, and the total prescribed dose at the isocenter ranged between 48 Gy in four fractions and 84 Gy in ten fractions. Median follow-up duration was 33 months. No patient had local failure nor regional lymph node failure. The 3-year rate of distant failure was 2.6%. Two patients who experienced distant metastases had a past surgical history of initial lung cancer before SBRT. The rates of cause-specific and overall survival at 3 years were 98.2 and 94.6%, respectively. Treatment-related adverse events of ≥grade 4 were not reported. Although more cases and longer follow-ups are mandatory, SBRT may be one of the radical treatment options for patients with GGN.

DOI： 10.1093/jrr/rraa015

PubMed

Language：English   Publishing type：Research paper (scientific journal)  

We quantified intra-fractional dose variation and organ movement during CT-based 3D-image guided brachytherapy (3D-IGBT) in cervical cancer patients. Fifteen patients who underwent CT-based 3D-IGBT were studied. For all patients, pre-delivery CT for treatment planning after applicator insertion and post-delivery CT after dose delivery without changing the applicator position were acquired. Pre- and post-delivery CT were rigidly fused by matching the inserted applicator and planned dose on pre-delivery CT (pre-delivery dose) was mapped on post-delivery CT (post-delivery dose). D2, D1, and D0.1 cm3 of the rectum and bladder were compared between pre- and post-delivery doses with contours on each CT image. Organ movement and deformation was evaluated using deformation vector fields calculated by deformable image registration between pre- and post-delivery CT. We also evaluated dose variation and DVF between with and without a catheter to control filling. Differences in all DVH parameters were <±3% in physical dose and ± 5% in EQD2. However, a > 15% dose difference was found in 13.8% of the fractions in rectum D2 cm3 and in 11.1% of those in bladder D2 cm3. The mean value of DVF for bladder was larger than that of rectum, especially for the superior-inferior (S-I) direction. Insertion catheters in bladder reduced mean dose and DVF variation compared with that of without catheters. In fraction groups with large dose increasing, DVF in the S-I direction was significantly larger than that of other fraction groups. Our results indicated that preparation is needed to reduce changes in the S-I direction affect dose variation.

DOI： 10.1016/j.ejmp.2020.04.009

PubMed

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

This study aimed to evaluate the rectal dose reduction with hydrogel spacer in 3D conformal radiotherapy (3DCRT), volumetric modulated arc therapy (VMAT), helical tomotherapy (HT), CyberKnife (CK) and proton therapy. Twenty patients who had hydrogel spacer for prostate radiotherapy were retrospectively enrolled. Computed tomography (CT) images with or without hydrogel spacer were used to evaluate rectal dose reduction. In total, 200 plans (20 patients × 2 CT images × 5 techniques) were created using the following criteria: 3DCRT, VMAT and HT [76 Gy/38 fractions (Fr), planning target volume (PTV) D50%], CK (36.25 Gy/5 Fr, PTV D95%) and proton therapy (63 GyE/21 Fr, PTV D50%). Rectal dose reduction was evaluated using low-/middle-dose (D20%, D50% and D80%) and high-dose (D2%) ranges. Rectal dose reduction of each dose index was compared for each technique. Significant rectal dose reduction (P < 0.001) between the treatment plans on pre- and post-CT images were achieved for all modalities for D50%, D20% and D2%. In particular, the dose reduction of high-dose (D2%) ranges were -40.61 ± 11.19, -32.44 ± 5.51, -25.90 ± 9.89, -13.63 ± 8.27 and -8.06 ± 4.19%, for proton therapy, CK, HT, VMAT and 3DCRT, respectively. The area under the rectum dose-volume histogram curves were 34.15 ± 3.67 and 34.36 ± 5.24% (P = 0.7841) for 3DCRT with hydrogel spacer and VMAT without hydrogel spacer, respectively. Our results indicated that 3DCRT with hydrogel spacer would reduce the medical cost by replacing the conventional VMAT without spacer for prostate cancer treatment, from the point of view of the rectal dose. For the high-dose gradient region, proton therapy and SBRT with CK showed larger rectal dose reduction than other techniques.

DOI： 10.1093/jrr/rraa013

PubMed

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

AIM: To evaluate the target dose coverage for lung stereotactic body radiotherapy (SBRT) using helical tomotherapy (HT) with the internal tumor volume (ITV) margin settings adjusted according to the degree of tumor motion. BACKGROUND: Lung SBRT with HT may cause a dosimetric error when the target motion is large. MATERIALS AND METHODS: Two lung SBRT plans were created using a tomotherapy planning station. Using these original plans, five plans with different ITV margins (4.0-20.0 mm for superior-inferior [SI] dimension) were generated. To evaluate the effects of respiratory motion on HT, an original dynamic motion phantom was developed. The respiratory wave of a healthy volunteer was used for dynamic motion as the typical tumor respiratory motion. Five patterns of motion amplitude that corresponded to five ITV margin sizes and three breathing cycles of 7, 14, and 28 breaths per minute were used. We evaluated the target dose change between a static delivery and a dynamic delivery with each motion pattern. RESULTS: The target dose difference increased as the tumor size decreased and as the tumor motion increased. Although a target dose difference of <5 % was observed at ≤10 mm of tumor motion for each condition, a maximum difference of -9.94 % ± 7.10 % was observed in cases of small tumors with 20 mm of tumor motion under slow respiration. CONCLUSIONS: Minimizing respiratory movement is recommended as much as possible for lung SBRT with HT, especially for cases involving small tumors.

DOI： 10.1016/j.rpor.2020.01.001

PubMed

Language：English   Publishing type：Research paper (scientific journal)   Publisher：SAGE Publications  

<sec><title>Background and Purpose:</title> We aimed to validate the usefulness of prescriptions based on gross tumor volume for stereotactic body radiotherapy for small peripheral lung tumors.

</sec><sec><title>Materials and Methods:</title> Radiotherapy treatment planning data of 50 patients with small peripheral lung tumors (adenocarcinoma: 24, squamous cell carcinoma: 10, other: 1, unknown: 15) receiving breath-hold computed tomography-guided stereotactic body radiotherapy at our institution during 2013–2016 were analyzed. For each case, 3 dose prescription methods were applied: one based on 95% (PTVD_95%) of the planning target volume, one based on 50% of the gross tumor volume (GTVD_50%), and one based on 98% (GTVD_98%) of the gross tumor volume. The maximum (GTVDmax), minimum (GTVDmin), and mean gross tumor volume dose (GTVDmean) and the dose covering 98% of the gross tumor volume were calculated to evaluate variations in the gross tumor volume dose.

</sec><sec><title>Results:</title> Upon switching to GTVD_50%, the variations in GTVDmax and GTVDmean decreased significantly, compared with variations observed for PTVD_95% (p &lt; 0.01), but the variation in GTVDmin increased significantly (p &lt; 0.01). Upon switching to the GTVD_98%, the variation in GTVDmean decreased significantly compared with that observed for PTVD_95% (p &lt; 0.01).

</sec><sec><title>Conclusion:</title> Switching from prescriptions based on 95% of the planning target volume to those based on 98% of the gross tumor volume decreased variations among cases in the overall gross tumor volume dose. Overall, prescriptions based on 98% of the gross tumor volume appear to be more suitable than those based on 95% of the planning target volume in cases of small peripheral lung tumors treated with stereotactic body radiotherapy.

</sec>

DOI： 10.1177/1533033820974030

PubMed

Other Link： http://journals.sagepub.com/doi/full-xml/10.1177/1533033820974030

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/j.rpor.2019.12.005

PubMed

Language：Japanese   Publishing type：Research paper (scientific journal)  

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/j.meddos.2019.04.007

PubMed

Language：Japanese   Publishing type：Research paper (bulletin of university, research institution)   Publisher：山梨肺癌研究会  

局所進行非小細胞肺癌に対する化学療法併用時の放射線治療は総線量として少なくとも60Gyを用いるよう、また脊髄(最大線量≦50Gy)や肺(V20≦35-40%、平均線量≦20Gy)の線量制約を遵守するよう推奨されている。症例によっては病変の位置、大きさなどによって脊髄や肺の線量制約が遵守できず、根治線量の投与が困難な場合がある。強度変調回転照射法(Volumetric modulated arc therapy:VMAT)は短時間で強度変調放射線治療(Intensity Mｏdulated Radiation Therapy:IMRT)が行える手法であり、固定多門によるIMRTと比較して息止め下で行う胸部病変の治療に適している。今回、従来の三次元原体照射法(three-dimensional conformal radiation therapy:3D-CRT)では根治線量投与が困難な局所進行肺癌症例に対して息止め下VMATを用いて根治的化学放射線療法を施行した初期経験を報告する。

DOI： 10.34429/00004828

CiNii Books

Language：English   Publishing type：Research paper (scientific journal)  

Deformable image registration (DIR) has recently become commercially available in the field of radiotherapy. However, there was no detailed information regarding the use of DIR software at each medical institution. Thus, in this study, we surveyed the status of the clinical use of DIR software for radiotherapy in Japan. The Japan Society of Medical Physics and the Japanese Society for Radiation Oncology mailing lists were used to announce this survey. The questionnaire was created by investigators working under the research grant of the Japanese Society for Radiation Oncology (2017-2018) and intended for the collection of information regarding the use of DIR in radiotherapy. The survey was completed by 161 institutions in Japan. The survey results showed that dose accumulation was the most frequent purpose for which DIR was used in clinical practice (73%). Various commissioning methods were performed, although they were not standardized. Qualitative evaluation with actual patient images was the most commonly used method (28%), although 30% of the total number of responses (42% of institutions) reported that they do not perform commissioning. We surveyed the current status of clinical use of DIR software for radiotherapy in Japan for the first time. Our results indicated that a certain number of institutions used DIR software for clinical practice, and various commissioning methods were performed, although they were not standardized. Taken together, these findings highlight the need for a technically unified approach for commissioning and quality assurance for the use of DIR software in Japan.

DOI： 10.1093/jrr/rrz034

PubMed

Language：English   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publishing type：Research paper (bulletin of university, research institution)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Purpose To assess changes in left ventricular function and tissue composition by using MRI after chemotherapy-radiation therapy in participants with esophageal cancer. Materials and Methods Between January 2013 and April 2015, this prospective study enrolled 24 participants (42% women; mean age, 63 years; range, 49-73 years) scheduled for chemotherapy-radiation therapy. 3.0-T MRI examinations were performed before, at 0.5 year, and at 1.5 years after chemotherapy-radiation therapy. Myocardial native T1, postcontrast T1, and extracellular volume were measured in basal septum (as irradiated areas) and apical lateral wall (as nonirradiated areas). Left ventricular function, prevalence of late gadolinium enhancement, and T1 and extracellular volume values were compared over the follow-up period by using Friedman or Cochran Q tests, followed by Dunn test. Results In 14 participants who were followed up for 1.5 years, native T1 and extracellular volume in the septum were elevated at 0.5 year compared with baseline (1183 msec ± 46 [standard deviation] vs 1257 msec ± 35; 26% ± 3 vs 32% ± 3; adjusted P < .01 for both), but not in the lateral wall. Left ventricular stroke volume index and late gadolinium enhancement changed at 1.5 years compared with baseline (41 mL/m2 ± 11 vs 36 mL/m2 ± 9; P = .046; 7% [one of 14] vs 78% [11 of 14]; P < .01). Other measures of left ventricular function did not change during the follow-up period (P > .10 for all). Conclusion Native T1 and extracellular volume could detect early changes in myocardium at 0.5 year after chemotherapy-radiation therapy, whereas left ventricular stroke volume index and late gadolinium enhancement showed abnormality at 1.5 years. © RSNA, 2018 Online supplemental material is available for this article.

DOI： 10.1148/radiol.2018172076

PubMed

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.4236/jmp.2018.913144

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1155/2018/5919467

Language：English   Publishing type：Research paper (scientific journal)   Publisher：John Wiley and Sons Ltd  

The purpose of this study was to compare the MLC error sensitivity of various measurement devices for VMAT pre-treatment quality assurance (QA). This study used four QA devices (Scandidos Delta4, PTW 2D-array, iRT systems IQM, and PTW Farmer chamber). Nine retrospective VMAT plans were used and nine MLC error plans were generated for all nine original VMAT plans. The IQM and Farmer chamber were evaluated using the cumulative signal difference between the baseline and error-induced measurements. In addition, to investigate the sensitivity of the Delta4 device and the 2D-array, global gamma analysis (1%/1, 2%/2, and 3%/3 mm), dose difference (1%, 2%, and 3%) were used between the baseline and error-induced measurements. Some deviations of the MLC error sensitivity for the evaluation metrics and MLC error ranges were observed. For the two ionization devices, the sensitivity of the IQM was significantly better than that of the Farmer chamber (P &lt
 0.01) while both devices had good linearly correlation between the cumulative signal difference and the magnitude of MLC errors. The pass rates decreased as the magnitude of the MLC error increased for both Delta4 and 2D-array. However, the small MLC error for small aperture sizes, such as for lung SBRT, could not be detected using the loosest gamma criteria (3%/3 mm). Our results indicate that DD could be more useful than gamma analysis for daily MLC QA, and that a large-area ionization chamber has a greater advantage for detecting systematic MLC error because of the large sensitive volume, while the other devices could not detect this error for some cases with a small range of MLC error.

DOI： 10.1002/acm2.12288

Scopus

PubMed

Language：English   Publishing type：Research paper (other science council materials etc.)  

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：John Wiley and Sons Ltd.  

Purpose: To evaluate the basic performance of a respiratory gating system using an Elekta linac and an Abches respiratory-monitoring device. Methods: The gating system was comprised of an Elekta Synergy linac equipped with a ResponseTM gating interface module and an Abches respiratory-monitoring device. The latencies from a reference respiratory signal to the resulting Abches gating output signal and the resulting monitor-ion-chamber output signal were measured. Then, the flatness and symmetry of the gated beams were measured using a two-dimensional ionization chamber array for fixed and arc beams, respectively. Furthermore, the beam quality, TPR20,10, and the output of the fixed gated beams were also measured using a Farmer chamber. Each of the beam characteristics was compared with each of those for nongated irradiation. Results: The full latencies at beam-on and beam-off for 6-MV gated beams were 336.4 ± 23.4 ms and 87.6 ± 7.1 ms, respectively. The differences in flatness between the gated and nongated beams were within 0.91% and 0.87% for the gun-target and left-right directions, respectively. In the same manner, the beam symmetries were within 0.68% and 0.82%, respectively. The percentage differences in beam quality and beam output were below 1% for a beam-on time range of 1.1-7 s. Conclusion: The latency of the Elekta gating system combined with Abches was found to be acceptable using our measurement method. Furthermore, we demonstrated that the beam characteristics of the gating system using our respiratory indicator were comparable with the nongated beams for a single-arc gated beam delivery.

DOI： 10.1002/mp.12664

Scopus

PubMed

Authorship：Lead author   Language：English  

Language：Japanese   Publishing type：(MISC) Summary of the papers read (national conference and other science council)   Publisher：(一社)日本癌治療学会  

Language：English  

Language：English   Publishing type：Research paper (scientific journal)   Publisher：WILEY  

The purpose of this study was comparing dose-volume histogram (DVH)-based plan verification methods for volumetric modulated arc therapy (VMAT) pretreatment QA. We evaluated two 3D dose reconstruction systems: ArcCHECK-3DVH system (Sun Nuclear corp.) and Varian dynalog-based dose reconstruction (DBDR) system, developed in-house. Fifteen prostate cancer patients (67.6 Gy/26 Fr), four head and neck cancer patient (66 Gy/33 Fr), and four esophagus cancer patients (60 Gy/30 Fr) treated with VMAT were studied. First, ArcCHECK measurement was performed on all plans; simultaneously, the Varian dynalog data sets that contained the actual delivered parameters (leaf positions, gantry angles, and cumulative MUs) were acquired from the Linac control system. Thereafter, the delivered 3D patient dose was reconstructed by 3DVH software (two different calculating modes were used: High Sensitivity (3DVH-HS) and Normal Sensitivity (3DVH-NS)) and in-house DBDR system. We evaluated the differences between the TPS-calculated dose and the reconstructed dose using 3D gamma passing rates and DVH dose index analysis. The average 3D gamma passing rates (3%/3 mm) between the TPS-calculated dose and the reconstructed dose were 99.1 +/- 0.6%, 99.7 +/- 0.3%, and 100.0 +/- 0.1% for 3DVH-HS, 3DVH-NS, and DBDR, respectively. For the prostate cases, the average differences between the TPS-calculated dose and reconstructed dose in the PTV mean dose were 1.52 +/- 0.50%, +/- 0.14 +/- 0.55%, and -0.03 +/- 0.07% for 3DVH-HS, 3DVH-NS, and DBDR, respectively. For the head and neck and esophagus cases, the dose difference to the TPS-calculated dose caused by an effect of heterogeneity was more apparent under the 3DVH dose reconstruction than the DBDR. Although with some residual dose reconstruction errors, these dose reconstruction methods can be clinically used as effective tools for DVH-based QA for VMAT delivery.

DOI： 10.1002/acm2.12123

Web of Science

PubMed

Language：English   Publishing type：Research paper (other science council materials etc.)  

Language：Japanese   Publishing type：(MISC) Summary of the papers read (national conference and other science council)   Publisher：(公財)東京都福祉保健財団人材養成部職員研修室  

Language：English   Publishing type：Research paper (scientific journal)   Publisher：ELSEVIER SCIENCE INC  

Purpose: To assess the accuracy of the commercially available deformable image registration (DIR) software for thoracic images at multiple institutions.
Methods and Materials: Thoracic 4-dimensional (4D) CT images of 10 patients with esophageal or lung cancer were used. Datasets for these patients were provided by DIR-lab (dir-lab.com) and included a coordinate list of anatomic landmarks (300 bronchial bifurcations) that had been manually identified. Deformable image registration was performed between the peak-inhale and -exhale images. Deformable image registration error was determined by calculating the difference at each landmark point between the displacement calculated by DIR software and that calculated by the landmark.
Results: Eleven institutions participated in this study: 4 used RayStation (RaySearch Laboratories, Stockholm, Sweden), 5 used MIM Software (Cleveland, OH), and 3 used Velocity (Varian Medical Systems, Palo Alto, CA). The ranges of the average absolute registration errors over all cases were as follows: 0.48 to 1.51 mm (right-left), 0.53 to 2.86 mm (anterior-posterior), 0.85 to 4.46 mm (superior-inferior), and 1.26 to 6.20 mm (3-dimensional). For each DIR software package, the average 3-dimensional registration error (range) was as follows: RayStation, 3.28 mm (1.26-3.91 mm); MIM Software, 3.29 mm (2.17-3.61 mm); and Velocity, 5.01 mm (4.02-6.20 mm). These results demonstrate that there was moderate variation among institutions, although the DIR software was the same.
Conclusions: We evaluated the commercially available DIR software using thoracic 4D-CT images from multiple centers. Our results demonstrated that DIR accuracy differed among institutions because it was dependent on both the DIR software and procedure. Our results could be helpful for establishing prospective clinical trials and for the widespread use of DIR software. In addition, for clinical care, we should try to find the optimal DIR procedure using thoracic 4D-CT data. (C) 2016 Elsevier Inc. All rights reserved.

DOI： 10.1016/j.ijrobp.2016.05.012

Web of Science

PubMed

Language：English   Publishing type：(MISC) Summary of the papers read (international conference)   Publisher：WILEY  

DOI： 10.1118/1.4957423

Web of Science

Language：English  

Language：English   Publishing type：Research paper (international conference proceedings)  

Language：English  

Language：English  

Authorship：Lead author   Language：Japanese   Publishing type：(MISC) Summary of the papers read (national conference and other science council)  

Authorship：Lead author   Language：English   Publishing type：Research paper (international conference proceedings)  

Total pages：96   Responsible for pages：13-16   Language：Japanese  

Total pages：1255   Responsible for pages：312-318   Language：Japanese   Book type：Textbook, survey, introduction

Event date： 2024.5

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：プラザヴェルデ　ふじのくに千本松フォーラム　コンベンションホールB   Country：Japan  

Event date： 2024.3

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：東京コンベンションホール.   Country：Japan  

Event date： 2023.12

Language：Japanese   Presentation type：Symposium workshop panel(nominated)  

Venue： 山梨大学キャンパス内　大学会館ラウンジ.   Country：Japan  

Event date： 2023.12

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：有明セントラルタワーホール＆カンファレンス   Country：Japan  

Event date： 2023.12

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：有明セントラルタワーホール＆カンファレンス   Country：Japan  

Event date： 2023.11 - 2023.12

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：パシフィコ横浜ノース   Country：Japan  

Event date： 2023.11 - 2023.12

Language：Japanese   Presentation type：Poster presentation  

Venue：パシフィコ横浜ノース   Country：Japan  

Event date： 2023.11 - 2023.12

Language：Japanese   Presentation type：Poster presentation  

Venue：パシフィコ横浜ノース   Country：Japan  

Event date： 2023.11

Language：English   Presentation type：Poster presentation  

Venue：Malaysia   Country：Malaysia  

Event date： 2023.7

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：山梨大学医学部　シミックプラザ　及び　Web配信   Country：Japan  

Event date： 2023.4

Language：English   Presentation type：Oral presentation(general)  

Country：Japan  

Event date： 2023.4

Language：Japanese   Presentation type：Oral presentation(general)  

Country：Japan  

Event date： 2023.3

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2023.2

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：仙台+オンライン  

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：仙台+オンライン  

Event date： 2023.2

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：オンライン開催  

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：オンライン開催  

Event date： 2023.2

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：Web開催  

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：Web開催  

Event date： 2022.12

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：Web開催  

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：Web開催  

Event date： 2022.11

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：Web開催  

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：Web開催  

Event date： 2022.8

Language：Japanese   Presentation type：Poster presentation  

Venue：山梨大学医学部　シミックプラザ  

Language：Japanese   Presentation type：Poster presentation  

Venue：山梨大学医学部 シミックプラザ  

Event date： 2022.7

Language：Japanese   Presentation type：Oral presentation(invited, special)  

Venue：甲府記念日ホテル/オンデマンド配信  

Language：Japanese   Presentation type：Oral presentation(invited, special)  

Venue：甲府記念日ホテル/オンデマンド配信  

Event date： 2022.6

Language：Japanese   Presentation type：Oral presentation(invited, special)  

Venue：オンライン（Zoom Webinar)  

Language：Japanese   Presentation type：Oral presentation(invited, special)  

Venue：オンライン（Zoom Webinar)  

Event date： 2022.5

Language：Japanese   Presentation type：Oral presentation(invited, special)  

Venue：東京都  

Language：Japanese   Presentation type：Oral presentation(invited, special)  

Venue：東京都  

Event date： 2022.3

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：Web開催.  

Event date： 2022.3

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2022.3

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：Web開催.  

Event date： 2022.2

Language：Japanese   Presentation type：Other  

Venue：Web開催  

Event date： 2022.2

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Language：Japanese   Presentation type：Other  

Venue：Web開催  

Event date： 2021.12

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：Web配信  

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：Web配信  

Event date： 2021.11

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：メルキュールホテル横須賀  

Event date： 2021.11

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：メルキュールホテル横須賀  

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：メルキュールホテル横須賀  

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：メルキュールホテル横須賀  

Event date： 2021.11

Language：Japanese   Presentation type：Oral presentation(invited, special)  

Venue：オンライン開催  

Language：Japanese   Presentation type：Oral presentation(invited, special)  

Venue：オンライン開催  

Event date： 2021.11

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：オンライン開催  

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：オンライン開催  

Event date： 2021.11

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：オンライン開催  

Event date： 2021.11

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：東京ビッグサイト  

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：東京ビッグサイト  

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：オンライン開催  

Event date： 2021.10

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：Web開催  

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：Web開催  

Event date： 2021.7

Language：Japanese   Presentation type：Oral presentation(invited, special)  

Venue：Web開催  

Language：Japanese   Presentation type：Oral presentation(invited, special)  

Venue：Web開催  

Event date： 2021.3

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：Web開催  

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：Web開催  

Event date： 2020.11

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：Web開催  

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：Web開催  

Event date： 2020.11

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：新潟＆Web開催  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2020.10

Language：English   Presentation type：Poster presentation  

Language：English   Presentation type：Poster presentation  

Venue：Web開催  

Event date： 2020.10

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：Web開催  

Event date： 2020.10

Language：English   Presentation type：Oral presentation(general)  

Event date： 2020.10

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：Web開催  

Event date： 2020.10

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：Web開催  

Event date： 2020.10

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：Web開催  

Event date： 2020.10

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：Web開催  

Language：Japanese   Presentation type：Poster presentation  

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：Web開催  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：English   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：Web開催  

Language：Japanese   Presentation type：Poster presentation  

Event date： 2020.7

Language：English   Presentation type：Poster presentation  

Venue：Web開催  

Language：English   Presentation type：Poster presentation  

Venue：Web開催  

Event date： 2020.5

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：Web開催  

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Event date： 2020.2

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：千葉  

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Event date： 2020.1

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：東京  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2019.11

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2019.11

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2019.11

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：名古屋  

Event date： 2019.11

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2019.11

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2019.11

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Poster presentation  

Language：Japanese   Presentation type：Poster presentation  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(invited, special)  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Poster presentation  

Event date： 2019.11

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2019.9

Language：English   Presentation type：Poster presentation  

Venue：Chicago, USA  

Language：English   Presentation type：Poster presentation  

Venue：Chicago, USA  

Event date： 2019.9

Language：English   Presentation type：Poster presentation  

Venue：Chicago, USA  

Language：English   Presentation type：Poster presentation  

Event date： 2019.9

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：福井  

Language：Japanese   Presentation type：Oral presentation(invited, special)  

Event date： 2019.7

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：東京  

Language：Japanese   Presentation type：Oral presentation(invited, special)  

Event date： 2019.6

Language：English  

Language：English   Presentation type：Oral presentation(general)  

Event date： 2019.5

Language：English   Presentation type：Poster presentation  

Venue：Odaiba, Tokyo  

Event date： 2019.5

Language：English   Presentation type：Oral presentation(general)  

Venue：Odaiba, Tokyo  

Event date： 2019.5

Language：English   Presentation type：Oral presentation(general)  

Venue：Odaiba, Tokyo  

Language：English   Presentation type：Poster presentation  

Language：English   Presentation type：Oral presentation(general)  

Language：English   Presentation type：Oral presentation(general)  

Event date： 2019.4

Language：Japanese  

Event date： 2019.4

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2019.3

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(invited, special)  

Event date： 2019.3

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2019.3

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：山梨大学  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2019.3

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：東京  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2018.12

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：埼玉  

Event date： 2018.10

Language：English   Presentation type：Poster presentation  

Venue：Texas, USA  

Language：English   Presentation type：Poster presentation  

Venue：Texas, USA  

Event date： 2018.10

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2018.10

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2018.10

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2018.10

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2018.10

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2018.10

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：English   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2018.6

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：上野  

Language：Japanese   Presentation type：Symposium workshop panel(nominated)  

Event date： 2018.6

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：日本橋  

Language：Japanese   Presentation type：Symposium workshop panel(nominated)  

Language：English   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2018.2

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2017.12

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2017.12

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2017.11

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2017.11

Language：English   Presentation type：Oral presentation(general)  

Event date： 2017.11

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2017.11

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2017.11

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2017.11

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：English   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Poster presentation  

Language：Japanese   Presentation type：Poster presentation  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2017.7

Language：English   Presentation type：Oral presentation(general)  

Event date： 2017.7

Language：English   Presentation type：Poster presentation  

Venue：Denver, USA  

Language：English   Presentation type：Poster presentation  

Language：English   Presentation type：Poster presentation  

Venue：Denver, USA  

Event date： 2017.7

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Venue：栃木  

Language：Japanese   Presentation type：Public discourse, seminar, tutorial, course, lecture and others  

Event date： 2017.6

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2017.6

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(invited, special)  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2017.6

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2017.6

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2017.5

Language：English   Presentation type：Oral presentation(general)  

Venue：Kobe  

Language：English   Presentation type：Oral presentation(general)  

Venue：Kobe  

Event date： 2017.4

Language：English   Presentation type：Oral presentation(general)  

Venue：Yokohama  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2017.3

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2017.3

Language：Japanese   Presentation type：Poster presentation  

Venue：仙台  

Event date： 2017.3

Language：Japanese   Presentation type：Oral presentation(general)  

Venue：仙台  

Language：Japanese   Presentation type：Poster presentation  

Language：Japanese   Presentation type：Poster presentation  

Event date： 2016.11

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2016.11

Language：English   Presentation type：Oral presentation(general)  

Venue：Kyoto  

Event date： 2016.11

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2016.11

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Poster presentation  

Language：Japanese   Presentation type：Poster presentation  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：English   Presentation type：Oral presentation(general)  

Event date： 2016.2

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2015.11

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2015.10

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2015.10

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2015.7

Language：English   Presentation type：Oral presentation(general)  

Language：English   Presentation type：Oral presentation(general)  

Event date： 2015.4

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2015.4

Language：English   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2014.10

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)  

Event date： 2014.8

Language：Japanese   Presentation type：Oral presentation(general)  

Language：Japanese   Presentation type：Oral presentation(general)